Cascia
Cascia
Chief Executive Officer & Founder
James Cour has more than 30 years of global healthcare leadership experience, including senior corporate roles at $6 billion Baxter International. He previously served as President of a NASDAQ‑listed regenerative medicine company and oversaw the launch of a first‑in‑class autologous cell therapy in Europe. Mr. Cour is the inventor of Cascia’s core technologies and architect of the company’s development pipeline. His background spans clinical operations, commercialization, corporate finance, M&A, and strategic planning.
Interim Chief Financial Officer
Glenn Charlesworth is a senior finance leader with extensive experience across public and private companies. He has led complex transactions including a $50M SPAC reverse acquisition and equity recapitalization. Mr. Charlesworth brings deep expertise in SEC reporting, audit oversight, and financial restructuring. His background includes building financial systems that support scalable growth and operational discipline. At Cascia, he guides financial strategy, capital planning, and readiness for national deployment.
(Name not disclosed on website)
Cascia’s VP of Bioengineering is a global leader in 3D biofabrication and advanced tissue engineering. He has built and scaled biofabrication platforms across Europe and North America and has authored more than 25 peer‑reviewed publications. His work includes securing multimillion‑dollar funding and translating laboratory innovations into clinically relevant systems. He specializes in multi‑material fabrication, robotics integration, and hospital‑based manufacturing. At Cascia, he leads platform engineering and the development of next‑generation regenerative technologies.
Medical Director
Dr. Erkan Özgün is a physician with more than 35 years of clinical leadership in emergency medicine, regenerative medicine, and translational research. He founded a stem‑cell therapy company and has published work in areas including ALS and spinal cord injury. Dr. Özgün provides medical governance, clinical oversight, and scientific credibility across Cascia’s platform. His experience spans both clinical practice and the development of regenerative workflows. At Cascia, he leads physician engagement and clinical integration.
Vice President, Development — Europe & Adjacent Markets
Mr. Francisco Vidal launched the first commercial hematopoietic stem‑cell product and has deep experience across European and adjacent markets in regenerative therapy. His background spans engineering, clinical support, and commercial development, giving him a broad understanding of hospital adoption dynamics. Mr. Vidal has built strong networks across clinical and operational stakeholders in multiple regions. He focuses on channel development, early deployment, and scalable market entry. At Cascia, he leads expansion across Europe and adjacent markets.
Director of Clinical Operations & Physician Engagement
Dr. Susan Cour leads clinical workflow integration, protocol execution, and site readiness across Cascia’s hospital deployments. She is the primary interface for physician engagement and onboarding, supporting clinicians across multiple specialties. Dr. Cour previously served in the U.S. Army Medical Corps and has spent a decade embedded in the development of Cascia’s platform. Her background spans patient care, clinical operations, and multidisciplinary team coordination. At Cascia, she ensures that hospital partners achieve consistent, high‑quality operational performance.